Q-Line Biotech IPO: Pricing, Financials, and Valuation Review
A detailed look at Q-Line Biotech Ltd's SME IPO, covering its diagnostics product portfolio, financial performance, valuation multiples, and subscription terms.
Live Grey Market Premium
Today's IPO GMP, subscription figures, and estimated listing gains.
| Company | Price band | GMP | Est. listing | Status |
|---|---|---|---|---|
|
Black Opal Sme |
₹0–₹0 | ₹0 (0.0%) | ₹0 | Listed |
|
Pind Hospitality Sme |
₹0–₹0 | ₹0 (0.0%) | ₹0 | Listed |
|
Q-Line Biotech Sme |
₹0–₹0 | ₹0 (0.0%) | ₹0 | Listed |
GMP figures reflect unofficial grey-market trading and can change quickly — not a guaranteed listing price.
Latest analysis
Visit the blog
Q-Line Biotech IPO: Pricing, Financials, and Valuation Review
A detailed look at Q-Line Biotech's maiden SME IPO, examining its diagnostics product portfolio, financial volatility,…
Q-Line Biotech IPO: Valuation, Financials, and Expert Review
Q-Line Biotech Ltd is launching its maiden book-building IPO to raise up to Rs. 214.48 crore.…
Q-Line Biotech IPO: Pricing, Financials, and Valuation Review
An in-depth review of the Q-Line Biotech IPO, covering its business segments, financial inconsistencies, valuation, and…
Understanding the numbers
What is GMP?
The price IPO shares trade at in the unofficial grey market before listing — the premium over the issue price reflects unofficial demand, not a guaranteed price.
Why subscription matters more
QIB (institutional) subscription is the more reliable signal — institutions do deep diligence before bidding. High GMP with weak QIB demand is worth a second look.
How to read this table
Est. listing = price band top + current GMP. It's an estimate, not a forecast — GMP can and does swing right up to listing day.